12 ileri kurs1 - Kan Merkezleri ve Transfüzyon Derneği

Ulusal Kan Merkezleri ve Transfüzyon T›bb› Kursu XII - ‹leri Kurs
KAYNAKLAR
1. Shander A, Capellini MD, Goodnough LT: ‹ronoverload and toxicity: the hidden risk of multiple blood transfusions.
Vox Sanguinis, 2009, 1-13.
2. Ozment CP, Turi JL: ‹ronoverload following red blood cell transfusion and its impact on disease severity. Biochimica
et Biophysica Acta, 1990, 1790:694-701.
3. Duca L, Delbini P, nava I, vaja V, Fiorelli G, Capellini MD: Mutation analysis of hepcidin and ferroportin genes
in Italian prospective blood donors with iron overload. Am J Hematol, 2009, 84(9):592-593.
4. Brissot P. Diagnosis and current treatments for primary iron overload. Am J Hematol, 2007, 82:1140-1141.
5. Hershko C: Iron loading and its clinical implications. Am J Hematol, 2007, 82:1147-1148.
6. Novotny VMJ: Red cell transfusion in medicine: Future challenges. Transfusion Clinique et Biologique, 2007,
14:538-554.
7. Piga A. Filomeno L, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, capellini MD: High non transferin
boun iron levels and heart disease in thalassemia major.Am J Hematol, 2009, 84:20-33.
8. Pietrangelo A: Iron chelation beyond transfusion iron overload. Am J Hematol, 2007, 82:1142-1146.
9. Ameli M, beshaarti S, Nemati K, Zamani F. relationship between elevated liver enzyme with iron overload and
viral hepatitis in thalassemia major patients in Norhern Iran. Saudi Med. J, 2008, 29(11):1611-1615.
10. Vermylen C. What is new in iron overload. Eur J Pediatr, 2008, 167:377-381.
11. Wood J: Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol,2007,
82:1132-1135.
12. Ayd›nok Y: Talasemide demir yükü ve flelasyon (Editörler) Canatan D, Ayd›nok Y: Talasemi ve Hemoglobinopatiler:
Tan› ve Tedavi. 2007 Antalya. sayfa:159-173.
13. Taher A, Musallam KM, El Rassi F, Duca L, ‹nati A, Koussa S, Capellini MD: Levels of non transferin-bound
iron as an index of iron overload in patients with thalassemia intermedia. Br J Haematol, 2009, 146:569-572.
14. Ghugre Nr, Gonzalez-Gomez I, Butensky E, Noetzli L, Fischer R, Williams R, Harmatz P, Coates TD, Wood
JC: pattern of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease.
Am J Hematol, 2009, 84 :480- 483.
15. Callea F: Ironoverload and chronicallay transfused patients: numbers, sacles and clinical research. Am J Hematol,
2009, 84:471- 472.
16. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE: Microaary analysis of liver gene expression
in iron overload patients with sickle cell anemia and beta thalassemia. Am J Hematol, 2009, 84(6):328-
334.
17. Porter J: Concepts and goals in management of transfusional iron overload. Am J Hematol, 2007, 82:1136-
1139.
18. Mavrogeni S: Evaluation of myocardial iron overload using magnetic resonance imaging. Blood Transfus. 2009,
7(3):183 -187.
19. Papakonstantinou O, Alexopoulou E, Econopoulos N, Benekos O, kattamis A, Kostaridou S, Ladis V, Efstathopoulos
E, Gouliamos A, Kelekis NL: Assessment of iron distribution between liver, spleen, pancreas, bone marrow
and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia. J Magn Reson
Imaging, 2009, 29(4):853-859.
20. Leung AW, Chu WC, Lam WW Lee V, Li CK: Magnetic rosonance imaging assessment of cardiac and liver iron
load in transfusion dependent patients. Pediatr Blood Cancer, 2009, 17:1-6.
21. Capellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med, 2008, 8(7):663-
674.
22. Galanello R: New advances in iron chelation Hematologica, 2008, 2(1):194-200.
23. Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM: Managing iron overload in patients with myelodisplastic
syndromes with oral deferasirox therapy. Oncologist, 2009, 14(5):489-496.
- 128 -